Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC

Hu,Rong; Li,Tao; Hui,Kaiyuan; Chen,Zi; Wang,Nan; Wu,Xingping; Ge,Linyang; Zhou,Linfu

doi:10.3892/mmr.2020.11492

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC

Authors:
- Rong Hu
- Tao Li
- Kaiyuan Hui
- Zi Chen
- Nan Wang
- Xingping Wu
- Linyang Ge
- Linfu Zhou
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Tumor Laboratory, Department of Oncology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China, Department of Respiratory and Critical Care Medicine, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222006, P.R. China
Published online on: September 7, 2020 https://doi.org/10.3892/mmr.2020.11492
Pages: 3935-3943
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis of advanced non‑small cell lung cancer (NSCLC) is poor; therefore, identifying novel treatment strategies for patients with NSCLC is important. The present study aimed to investigate the efficacy of apatinib plus docetaxel vs. docetaxel alone, as well as their effects on regulating autophagy markers in patients with advanced NSCLC. Furthermore, it was evaluated whether apatinib sensitized chemoresistant NSCLC cells to docetaxel via regulating autophagy. A total of 39 patients with advanced NSCLC were consecutively enrolled and treated with apatinib plus docetaxel (n=19) or docetaxel alone (n=20) for four treatment cycles. The treatment response, adverse events and expression levels of autophagy markers [(light chain 3 α (LC3A) and Beclin‑1] were evaluated in tumor samples, which were obtained via biopsy, before treatment and after 2‑cycle treatment. In addition, in a mechanistic in vitro experiment, apatinib, docetaxel, the autophagy activator rapamycin and the autophagy inhibitor 3‑methyladenine (3‑MA) were used to treat docetaxel‑resistant A549 (A549/DTX) cells alone or in various combinations. The expression levels of LC3A, Beclin‑1, poly (ADP) ribose polymerase (PARP) and phosphorylated (p)‑AKT were detected via western blotting, while the cell apoptosis rate was detected with an Annexin V/PI assay. The overall remission rate (37 vs. 10%; P=0.047) and disease control rate (84 vs. 45%; P=0.011) were increased in the Apatinib plus docetaxel group compared with the Docetaxel group. Most of the adverse events were mild and tolerable, and there was no difference between the two groups except for total hypertension and hand‑foot syndrome, which were higher in the Apatinib plus docetaxel group). Compared with the levels prior to treatment, Beclin‑1 and LC3A remained unchanged post‑treatment in the Apatinib plus docetaxel group, while they were increased in the Docetaxel group. Docetaxel increased LC3A, Beclin‑1 and p‑AKT expression levels, PARP cleavage and the cell apoptosis rate in A549/DTX cells, and rapamycin further enhanced, while 3‑MA reduced these effects of docetaxel. Moreover, apatinib repressed LC3A, Beclin‑1, p‑AKT expression levels and promoted the cell apoptosis rate in A549/DTX cells and docetaxel‑treated A549/DTX cells. In conclusion, apatinib synergize the effect of docetaxel in treating patients with advanced NSCLC and chemoresistant NSCLC cells via inhibiting autophagy.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current therapies and new targeted treatments. Lancet. 389:299–311. 2017. View Article : Google Scholar : PubMed/NCBI
3	Tanino R, Tsubata Y, Harashima N, Harada M and Isobe T: Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer. Oncotarget. 9:16807–16821. 2018. View Article : Google Scholar : PubMed/NCBI
4	Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y, Li J and Lou L: YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380. 2011. View Article : Google Scholar : PubMed/NCBI
5	Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, et al: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer. 10:5292010. View Article : Google Scholar : PubMed/NCBI
6	Maroufi NF, Rashidi MR, Vahedian V, Akbarzadeh M, Fattahi A and Nouri M: Therapeutic potentials of apatinib in cancer treatment: Possible mechanisms and clinical relevance. Life Sci. 241:1171062020. View Article : Google Scholar : PubMed/NCBI
7	Wu F, Zhang S, Gao G, Zhao J, Ren S and Zhou C: Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review. Cancer Biol Ther. 19:141–144. 2018. View Article : Google Scholar : PubMed/NCBI
8	Duan JC, Wang ZJ, Lin L, Li JL, Wang Y, Bai H, Hu XS, Liu YT, Hao XZ, Wang HY, et al: Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: A phase I trial. Invest New Drugs. 37:731–737. 2019. View Article : Google Scholar : PubMed/NCBI
9	Jiang Q, Zhang NL, Ma DY, Tan BX, Hu X and Fang XD: Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study. Medicine (Baltimore). 98:e160652019. View Article : Google Scholar : PubMed/NCBI
10	Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP, Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, et al: Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 70:7981–7991. 2010. View Article : Google Scholar : PubMed/NCBI
11	Li J, Jia Y, Gao Y, Chang Z, Han H, Yan J and Qin Y: Clinical efficacy and survival analysis of apatinib combined with docetaxel in advanced esophageal cancer. Onco Targets Ther. 12:2577–2583. 2019. View Article : Google Scholar : PubMed/NCBI
12	Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
13	Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S and Bukhari N: Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 12:728–736. 2019. View Article : Google Scholar : PubMed/NCBI
14	Lencioni R and Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30:52–60. 2010. View Article : Google Scholar : PubMed/NCBI
15	Feng H, Cheng X, Kuang J, Chen L, Yuen S, Shi M, Liang J, Shen B, Jin Z, Yan J and Qiu W: Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer. Cell Death Dis. 9:10302018. View Article : Google Scholar : PubMed/NCBI
16	Lu W, Ke H, Qianshan D, Zhen W, Guoan X and Honggang Y: Apatinib has anti-tumor effects and induces autophagy in colon cancer cells. Iran J Basic Med Sci. 20:990–995. 2017.PubMed/NCBI
17	Liu K, Ren T, Huang Y, Sun K, Bao X, Wang S, Zheng B and Guo W: Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell Death Dis. 8:e30152017. View Article : Google Scholar : PubMed/NCBI
18	Fu H, Jin C, Zhu Q, Liu T, Ke B, Li A and Zhang T: Dysregulated expressions of PTEN, NF-kB, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia. Am J Transl Res. 11:1092–1101. 2019.PubMed/NCBI
19	Feng SQ, Wang GJ, Zhang JW, Xie Y, Sun RB, Fei F, Huang JQ, Wang Y, Aa JY and Zhou F: Combined treatment with apatinib and docetaxel in A549 ×enograft mice and its cellular pharmacokinetic basis. Acta Pharmacol Sin. 39:1670–1680. 2018. View Article : Google Scholar : PubMed/NCBI
20	Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, Wang L, Xia Y, Qiao Y, Sun W, et al: Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. J Exp Clin Cancer Res. 38:712019. View Article : Google Scholar : PubMed/NCBI
21	Bulatov E, Sayarova R, Mingaleeva R, Miftakhova R, Gomzikova M, Ignatyev Y, Petukhov A, Davidovich P, Rizvanov A and Barlev NA: Isatin-schiff base-copper (II) complex induces cell death in p53-positive tumors. Cell Death Discov. 4:1032018. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain SA, Fléchon A, Bamias A, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): Overall survival and updated results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 21:105–120. 2020. View Article : Google Scholar : PubMed/NCBI
24	Takahari D: Second-line chemotherapy for patients with advanced gastric cancer. Gastric Cancer. 20:395–406. 2017. View Article : Google Scholar : PubMed/NCBI
25	Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet. 384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI
26	Chen ZJ, Le HB, Zhang YK, Qian LY, Sekhar KR and Li WD: Lung resistance protein and multidrug resistance protein in non-small cell lung cancer and their clinical significance. J Int Med Res. 39:1693–1700. 2011. View Article : Google Scholar : PubMed/NCBI
27	Pan B, Chen D, Huang J, Wang R, Feng B, Song H and Chen L: HMGB1-mediated autophagy promotes docetaxel resistance in human lung adenocarcinoma. Mol Cancer. 13:1652014. View Article : Google Scholar : PubMed/NCBI
28	Chen T, Ren H, Thakur A, Yang T, Li Y, Zhang S, Wang T and Chen MW: Decreased level of klotho contributes to drug resistance in lung cancer cells: Involving in klotho-mediated cell autophagy. DNA Cell Biol. 35:751–757. 2016. View Article : Google Scholar : PubMed/NCBI